Actinium Pharmaceuticals Logo
US00507W2061
A2QA48
ATNM

Actinium Pharmaceuticals

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 10,07 € (+645,93 %). La mediana es de 4,50 € (+233,33 %).

Comprar
  11
Mantener
  0
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Actinium shows strong preclinical efficacy of ATNM-400 in NSCLC models

    Actinium presented preclinical data on ATNM-400, an Actinium-225–linked radioconjugate for non‑small cell lung cancer, at the Society of Nuclear Medicine annual meeting. In KRAS‑mutant models, ATNM-400 as monotherapy outperformed the KRAS inhibitors sotorasib and adagrasib and enhanced their tumor‑cell killing when combined. In EGFR‑mutant models, ATNM-400 achieved 75% tumor growth inhibition versus 40% for osimertinib; the combination produced complete tumor regressions in all treated mice. The target antigen was detectable in approximately 98% of NSCLC tumors, and investor assessments see upside potential for the stock despite high cash burn. » Más en de.investing.com


  • Actinium presents preclinical data on ATNM-400 and Actimab‑A at AACR on April 21

    Actinium will present posters with unpublished preclinical data on April 21 at the AACR annual meeting for ATNM-400 (an Ac‑225 radioconjugate for solid tumors) and Actimab‑A (a therapy for AML/MDS). ATNM-400 showed activity in models of metastatic, castration‑resistant prostate cancer as well as non‑small cell lung and breast cancer; Actimab‑A data illuminate a mechanism described as “transcriptional reprogramming.” The presentations are part of the session block “Radiopharmaceutical Platforms for Theranostic Precision Oncology”; Actimab‑A is being co‑developed with the National Cancer Institute. The stock is trading near its 52‑week low and the company reports high liquidity. » Más en de.investing.com


  • Actinium Pharmaceuticals rises after promising preclinical data on ATNM-400

    Actinium Pharmaceuticals' stock rose about 3.7% after the presentation of new preclinical data on ATNM-400 at the San Antonio Breast Cancer Symposium 2025. The Actinium-225–based antibody‑radioconjugate showed strong antitumor activity in several breast cancer models, including hormone receptor‑positive, triple‑negative and treatment‑resistant tumors, with a favorable tolerability profile. The data demonstrated irreversible double‑strand DNA breaks caused by the alpha‑emitter payload; Actinium plans to advance ATNM-400 as a monotherapy and in combinations and sees potential also in prostate and non‑small‑cell lung cancer. » Más en de.investing.com


  • Actinium: ATNM-400 shows efficacy in preclinical models of therapy-resistant breast cancer subtypes

    Actinium presents preclinical data demonstrating a tumor-inhibiting effect of ATNM-400 in hormone receptor–positive, HER2-positive and triple-negative breast cancer models that are resistant to tamoxifen or trastuzumab. In certain models, ATNM-400 produced tumor growth inhibition of more than 100% at higher doses. The Actinium-225 antibody–radioconjugate uses alpha particles, targets proteins that are overexpressed in association with resistance, and is designed to reduce the risk of unwanted lung toxicity. The data will be presented on December 11, 2025, at the San Antonio Breast Cancer Symposium; earlier preclinical results also showed promising effects in lung and prostate cancer. » Más en de.investing.com


  • Actinium Pharmaceuticals: shareholders elect directors and ratify audit and compensation proposals

    At the 2025 annual meeting, Ajit S. Shetty and June S. Almenoff were re-elected as Class III directors until the 2028 annual meeting. Shareholders ratified CBIZ as the independent registered public accounting firm for fiscal year 2025 and approved, in a non-binding advisory vote, the named executive officer compensation. In addition, a three-year cycle was established for future advisory votes on executive compensation. A total of 15,494,573 common shares were represented; all proposals submitted to a vote were approved. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, Actinium Pharmaceuticals tuvo unos ingresos de 30,67 M € y un beneficio neto de 24,45 M €
(EUR) junio de 2026
YoY
Ingresos 30,67 M -
Beneficio bruto 30,67 M -
Beneficio neto 24,45 M 518,94 %
EBITDA 24,66 M 535,48 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
46,9 M €
Número de acciones
31,44 M
Máximo/mínimo de 52 semanas
1,56 € - 0,67 €
Dividendos No
Beta
0,02
Ratio P/E
4,56
Ratio PEG
0,02
Ratio P/B
1,70
Ratio P/S
1,47

Perfil de la empresa

Actinium Pharmaceuticals, Inc., una empresa biofarmacéutica en fase clínica, se centra en el desarrollo y la comercialización de terapias para el trasplante de médula ósea (BMT) o un tipo de terapia celular, y para otras terapias de transferencia adoptiva de células. Su principal candidato a producto, I-131 apamistamab (Iomab-B), se encuentra en un ensayo clínico pivotal de fase III para leucemia mieloide aguda recidivante o refractaria en pacientes de edad avanzada, para el acondicionamiento previo al BMT; y un estudio de fase I con una terapia de células T CAR dirigida a CD19 con el Memorial Sloan Kettering Cancer Center. La empresa también ofrece programas de desarrollo clínicos y preclínicos que utilizan múltiples isótopos, entre ellos Actinio-225, Yodo-131 y Lutecio-177, dirigidos a múltiples dianas validadas en cáncer, como CD45, CD33, CD38, CD47, HER2 y HER3, para el acondicionamiento dirigido previo a terapias celulares y génicas, como el trasplante de médula ósea, y a tratamientos oncológicos como agentes únicos o en combinación con otras modalidades terapéuticas. Tiene una colaboración con Astellas Pharma, Inc. para desarrollar teranósticos para indicaciones de tumores sólidos; con EpicentRx, Inc., que se centra en una nueva radioterapia dirigida de inmunoterapia contra CD47; y con AVEO Oncology, que se centra en el desarrollo de un ARC dirigido a HER3 para tumores sólidos. La empresa se constituyó en 2000 y tiene su sede en Nueva York, Nueva York.

Nombre
Actinium Pharmaceuticals
CEO
Sandesh C. Seth
Sede New York City, ny
Estados Unidos
Sitio web
Industria
Productos químicos
Salida a bolsa
27/12/2012
Empleados 27

Símbolos bursátiles

Bolsa Símbolo
AMEX
ATNM
Frankfurt
7AY1.F
Düsseldorf
7AY1.DU
🍪

Parqet  usa cookies. Más información